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Abstract The C1 domains are 50 amino acid sequences present
in protein kinase C (PKC) isozymes that are responsible for
binding of phorbol esters and the lipid second messenger
diacylglycerol (DAG). We found that bacterially expressed
C1b domain of PKCN induces germinal vesicle breakdown
(GVBD) when microinjected into Xenopus laevis oocytes.
Injection of the C1b domain of PKCN significantly enhanced
insulin- but not progesterone-induced maturation. Interestingly,
the PKCN C1b domain markedly synergized with normal Ras
protein to induce oocyte maturation when both proteins were co-
injected in oocytes. Our results demonstrate that the purified C1b
domain of PKCN is sufficient to promote meiotic maturation of
X. laevis oocytes probably through activation of components of
the insulin/Ras signaling pathway. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
The C1 domains are 50/51 amino acid motifs that were
initially identi¢ed in the regulatory domain of protein kinase
C (PKC) isozymes, a family of kinases that play a critical
role in signaling events controlling cell proliferation, death
and di¡erentiation [1^5]. C1 domains possess the motif
HX12CX2CXnCX2CX4HX2CX7C, where H is His, C is Cys,
X is any other amino acid, and n is 13^14. This domain is
duplicated in tandem (C1a and C1b) in the calcium-dependent
or ‘classical’ PKCs (cPKCK, LI, LII, and Q), in the calcium-
independent or ‘novel’ PKCs (nPKCN, O, R, and a) and in the
PKC-related protein PKCW (PKD). A single C1 domain is
present in ‘atypical’ PKCs (aPKCj and V/S) and in proteins
unrelated to PKCs, including K- and L-chimaerins, RasGRP,
Caenorhabditis elegans Unc-13 and mammalian Munc-13 iso-
forms [4,6].
Mutagenesis and structural studies have revealed that the
C1 domains in the regulatory domain of cPKC and nPKCs
are responsible for the binding of phorbol esters and the sec-
ond messenger diacylglycerol (DAG) [1,7^9]. Using isolated
C1 domains of PKCs expressed in bacteria it was established
that the 50 amino acid region is the minimum domain for
phorbol ester binding [1,7^10]. The ligand binding properties
of isolated C1 domains are similar to those of the correspond-
ing holoenzymes [10,11]. Mutations in Cys or His that are
essential for folding of the domain abolished phorbol ester/
DAG binding [1,9]. Binding of phorbol esters/DAG to intact
PKCs or isolated C1 domains is dependent on phospholipids,
and phosphatidylserine is the most e⁄cient lipid for reconsti-
tution of binding [7,10,12]. Although highly homologous, in-
dividual C1 domains have shown remarkable di¡erences in
ligand recognition, suggesting that signi¢cant structural var-
iations might exist among the di¡erent C1 domains that con-
fer unique properties in each case [13,14].
The C1 domains are implicated in the association of cPKCs
and nPKCs to membranes after elevation of DAG levels or
phorbol ester treatment, a process known as ‘translocation’.
Allosteric activation of PKC involves the association of the
enzyme to membranes, and this association requires the C1
domain. Interestingly, studies have demonstrated non-equiva-
lent roles for C1a and C1b domains in PKC translocation
[15,16]. PKC isozymes distribute to di¡erent intracellular
compartments, and there is strong evidence that association
to speci¢c proteins upon translocation is a key mechanism
that determines localization for each isozyme [17,18]. Several
proteins have been identi¢ed that associate to di¡erent regions
in the regulatory domain of PKCs, including association to
the C1 domain [4,17,19^23]. Importantly, several studies have
demonstrated that the regulatory domain in PKC isozymes
can indeed evoke cellular responses, and in many cases even
mimic the action of the full-length protein [24^28]. This is
relevant because there is little evidence for substrate speci¢city
for PKC isozymes, and suggests a role for the regulatory
domain in conferring isozyme speci¢city through protein^pro-
tein association. The complexity of the interactions that occur
through the C1 domain and its potential for conferring iso-
zyme speci¢city is a subject of intense investigation.
In this paper we explore the hypothesis that C1 domains of
PKCs have in vivo functions using Xenopus laevis oocytes as a
model system. X. laevis oocytes are arrested at the G2/M
transition of the ¢rst meiotic prophase. Insulin and progester-
one induce oocytes to enter metaphase and undergo meiotic
maturation involving germinal vesicle breakdown (GVBD)
[29,30]. The possibility of inducing maturation by microinjec-
tion of various oncogene products makes the Xenopus oocyte
system a very useful experimental model for the analysis of in
vivo function(s) of various cellular gene products in the pro-
gression through the eukaryotic cell cycle. This model has
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been widely used to evaluate the relationship of PKC with
other signaling pathways [21,31,32]. The data presented here
show that an isolated C1b domain of the novel PKCN induces
maturation of oocytes, and accelerates insulin-induced matu-
ration.
2. Materials and methods
2.1. Materials
Glutathione-Sepharose 4B beads, benzamidine-Sepharose, reduced
glutathione and isopropyl-1-thio-L-D-galactopyranoside (IPTG) were
purchased from Pharmacia Biotech Inc. (Piscataway, NJ, USA). Am-
picillin, insulin and progesterone were obtained from Sigma. Bovine
plasminogen free thrombin and gonadotropin were from Calbiochem-
Novabiochem (La Jolla, CA, USA). All other chemicals were of high
quality.
2.2. Expression of the PKCN C1b domain in Escherichia coli
The PKCN C1b domain was expressed as a glutathione S-transfer-
ase (GST) fusion protein in E. coli. Generation of the expression
vector and expression of the recombinant protein are described else-
where [9,10]. Brie£y, a mouse cDNA fragment encoding the PKCN
C1b domain [9] was generated by polymerase chain reaction and sub-
cloned in-frame into the pGEX-TK vector (Pharmacia Biotech Inc.)
to get the pGEXN plasmid. In order to express the recombinant C1
domain as a GST fusion protein, JM101 cells were transformed with
the pGEXN plasmid and then grown in 1 l of LB medium containing
50 Wg/ml ampicillin. Expression of the GST fusion protein was in-
duced by the addition of 0.5 mM IPTG after the bacteria reached
an A600 of 0.5. Five hours later cells were pelleted at 4000Ug and
resuspended in 20 ml of phosphate-bu¡ered saline containing 3 mM
dithiothreitol. Cells were lysed by homogenization, passed two times
through a French press and sonicated. After centrifugation of the
lysate (15 000Ug at 4‡C, 45 min), the supernatant was collected and
incubated for 1 h at 4‡C with 10 ml of a 50% glutathione-Sepharose
4B suspension. The glutathione-Sepharose 4B beads were collected by
centrifugation (500Ug, 5 min), and the GST fusion protein was eluted
with 1 ml of 10 mM reduced glutathione in 50 mM Tris^Cl, pH 8.0.
The elution step was repeated an additional three times, and the
collected fractions were pooled. In order to cleave the PKCN C1b
domain from the GST partner, the solution was then treated with
thrombin (250 U, 4 h). This condition was su⁄cient to cleave all
the recombinant C1 domain, as judged by gel electrophoresis. Throm-
bin was then removed by incubation with benzamidine-Sepharose
beads according to the manufacturer’s instructions (Pharmacia). The
beads were then pelleted, and the supernatant puri¢ed by HPLC on
C4 silica gel using a gradient of 0.05% tri£uoroacetic acid/H2O: 0.05%
tri£uoroacetic acid in 90/10 CH3CN/H2O, from 75:25 to 25:75 over
30 min. The C1 domain and the residual GST eluted at 14.8 min and
18 min, respectively. The puri¢ed PKCN C1b domain was then re-
folded as described previously [10]. Brie£y, the C1 domain was dis-
solved in 0.05% tri£uoroacetic acid, pH 2.5, and 2.5^3 molar equiv-
alents (based on weight of protein) of Zn2 (as 50 mM ZnCl2) were
added, and the pH was slowly raised to 6.0 with NaOH. The solution
was desalted and concentrated on Centricon-3 ¢lters. A single peak
was found in the HPLC pro¢le after puri¢cation. A single band was
also observed after Coomassie blue staining of SDS^polyacrylamide
gels (see [10] for a ¢gure with HPLC pro¢le and Coomassie blue
staining). The activity of the protein was con¢rmed by [3H]phorbol
12,13-dibutyrate ([3H]PDBu) binding, using the method of Sharkey
and Blumberg [9^11,33]. This puri¢ed C1 domain has been also
used for X-ray crystallography analysis and structure determination
[8].
2.3. Mutants of the PKCN C1b domain
Mutants in position 22 of the PKCN C1b domain (which corre-
sponds to position 252 in the full-length protein) were generated by
site-directed mutagenesis using the U.S.E. Mutagenesis kit (Pharmacia
Biotech Inc.). In these mutants, Trp-252 was replaced by either Gly
(W252G-PKCN C1b) or Phe (W252F-PKCN C1b). The details of the
generation of these mutants are described elsewhere [9]. Expression of
the GST-PKCN C1b mutants in E. coli and puri¢cation of the re-
combinant protein were done as described above for the wild-type
PKCN C1b domain.
2.4. Expression and puri¢cation of non-transforming Ras
Expression and puri¢cation to homogeneity of non-transforming
H-Ras protein (Gly-12) was done as we have previously described
[34,35].
2.5. Expression and puri¢cation of the SH2 domain of p85 (PI3 kinase
(PI3K))
The SH2 domain of p85 (residues 333^428) of PI3K was cloned into
the bacterial expression vector pQE9 (Qiagen), and expressed and
puri¢ed to near homogeneity as previously described [36].
2.6. Oocyte preparation, microinjection and maturation
Adult female X. laevis (purchased from Nasco, Fort Atkinson, WI,
USA) were stimulated to ovulate by microinjecting 50 U of serum
gonadotropin 3 days before oocyte extraction. Ovarian fragments
were surgically removed from frogs anesthetized by hypothermia.
Full grown, stage VI oocytes were manually dissected into ND-96
medium (5 mM HEPES, 96 mM NaCl, 1 mM MgCl2, 2 mM KCl,
1.8 mM CaCl2, pH 7.8, 10 Wg/ml penicillin and 10 Wg/ml streptomycin
sulfate). The oocytes were allowed to recover overnight in the same
bu¡er before further treatment, and were constantly maintained at
20‡C. For induction of meiotic maturation, groups of 10 to 12 oocytes
were incubated in ND-96 medium without KCl in the presence of
progesterone (15 WM) or insulin (7.5 WM). In another set of experi-
ments, 30 to 60 nl of PKCN C1b protein or mutated forms of the
domain (1 Wg/Wl solutions made in 20 mM Tris^HCl, pH 7.5) were
microinjected into oocytes. Controls were microinjected with bu¡er.
For co-injection experiments, oocytes were ¢rst injected with 30 nl of
puri¢ed normal H-Ras protein or the SH2 domain of p85 (PI3K) (1
Wg/Wl) and then allowed to recover by incubating for 30 min in ND-96
medium before injecting them again with 30 nl of puri¢ed PKCN C1b
protein.
Meiotic maturation was assayed by scoring the disappearance of
the nucleus (GVBD) in oocytes ¢xed with 10% trichloroacetic acid
[37]. The absence of the nucleus correlated with the appearance of a
white spot in the animal pole. Periodic, routine assays indicated that
the absence of the nucleus correlated with the appearance of a white
spot on the animal pole and with activation of histone H1 kinase
activity (MPF kinase) in clari¢ed extracts of the oocytes [38,39].
2.7. Determination of protein concentration
Protein was determined by the method of Bradford [40], using bo-
vine serum albumin as standard.
3. Results
In our previous studies we have shown that the PKCN C1b
domain (Fig. 1) is the minimum domain for phorbol ester
binding in PKCN [9,10]. We expressed the PKCN C1b domain
in E. coli as a GST fusion protein, and recovered the protein
from bacterial lysates using glutathione-Sepharose 4B beads.
The GST partner was removed by thrombin digestion and the
recombinant protein puri¢ed by HPLC as described in Section
2. Phorbol ester binding analysis for the puri¢ed PKCN C1b
domain using the radioligand [3H]PDBu revealed a dissocia-
tion constant (Kd) of 0.8 þ 0.1 nM (n = 5), which is similar to
that observed with the holoenzyme [10,11]. The PKCN C1b
domain is therefore properly folded after puri¢cation, as pre-
viously con¢rmed by X-ray crystallography [8].
Fig. 1. Sequence of the PKCN C1b domain. The amino acid subjected to mutagenesis (Trp-252) is underlined.
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We evaluated the e¡ect of microinjection of the puri¢ed
PKCN C1b domain into full grown, stage VI X. laevis oocytes.
Interestingly, the PKCN C1b domain induced meiotic matura-
tion of the oocytes in a dose-dependent manner as determined
by GVBD (Fig. 2). We next assessed the e¡ect of a mutant of
the PKCN C1b domain, in which Trp-252 was replaced by Gly
(W252G-PKCN C1b). This mutant has approximately 30-fold
lower binding a⁄nity for [3H]PDBu compared to the wild-
type PKCN C1b domain [9]. We observed that W252G-
PKCN C1b was less e⁄cient than wild-type PKCN C1b at
inducing oocyte maturation (Fig. 3). We have also used a
mutated PKCN C1b domain in which Trp in position 252
has been replaced by Phe (W252F-PKCN C1b). This mutant
has similar binding a⁄nity for [3H]PDBu as the non-mutated
domain [9]. When microinjected into oocytes, W252F-PKCN
C1b induced maturation with similar potency as the wild-type
PKCN C1b domain (Fig. 3).
In order to begin elucidating the mechanism by which the
PKCN C1b domain induces oocyte maturation, we ¢rst eval-
uated whether microinjection of the PKCN C1b domain a¡ects
maturation induced by either insulin or progesterone. Activa-
tion of insulin or progesterone receptor induces oocyte matu-
ration through di¡erent signaling pathways. While progester-
one induces maturation mainly through inhibition of the
cAMP/PKA-dependent pathway, insulin activates maturation
through a receptor tyrosine kinase Ras-dependent mechanism
[36,41^43]. Interestingly, when the PKCN C1b domain was
injected into oocytes, we observed that it markedly accelerates
the maturation induced by insulin (Fig. 4A). As expected,
similar results were observed when the mutant W252F-
PKCN C1b was injected (data not shown). On the other
hand, microinjection of the PKCN C1b domain did not a¡ect
the kinetics of GVBD mediated by progesterone (Fig. 4B),
suggesting that the e¡ect is speci¢c for the insulin pathway.
In the next set of experiments we evaluated whether the
PKCN C1b domain a¡ects the e¡ect of Ras on maturation.
In contrast to transforming Ras variants, normal Ras proteins
(Gly-12) poorly induce maturation in oocytes [36]. Interest-
ingly, our experiments reveal that microinjection of the PKCN
C1b domain markedly potentiates the e¡ect of normal H-Ras
on oocyte maturation (Fig. 5A). In order to further elucidate
the mechanism of action of the PKCN C1b domain, we as-
sessed whether the e¡ect on oocyte maturation could be af-
fected by the SH2 domain of p85 (PI3K). We have previously
shown that the SH2 domain of p85 (PI3K) blocks insulin-
induced maturation of Xenopus oocytes [36]. When co-injected
with the PKCN C1b domain, the SH2 domain of p85 did not
block meiotic maturation, although it completely blocked the
e¡ect of insulin under the same experimental condition (Fig.
5B). Taken together, these experiments indicate that the
PKCN C1b domain exerts its e¡ect on oocytes through acti-
vation of the Ras-dependent insulin pathway.
Fig. 2. Induction of maturation of X. laevis oocytes by microinjec-
tion of PKCN C1b domain. Oocytes (10 to 12 for each experimental
condition) were injected with di¡erent amounts of the PKCN C1b
domain in 30 nl of 20 mM Tris^HCl, pH 7.5 bu¡er, and GVBD
was monitored for 32 h. Closed circles, 60 ng; open circles, 30 ng;
closed squares, 7.5 ng; open squares, 1.9 ng. Injection of bu¡er
alone did not induce any maturation. Results are expressed as a
percentage of oocytes reaching GVBD. The induction of oocyte
maturation by the PKCN C1b domain was observed in at least ¢ve
independent experiments.
Fig. 3. E¡ect of PKCN C1b domain mutants on oocyte maturation.
Each C1 domain (30 ng) was injected in groups of 10^12 oocytes
and GVBD was monitored. Results are expressed as a percentage of
oocytes reaching GVBD. Closed circles, wild-type (W.T.) PKCN
C1b domain; open circles, W252G-PKCN C1b domain; closed
squares, W252F-PKCN C1b domain. Similar results were observed
in two additional experiments.
Fig. 4. E¡ect of microinjection of PKCN C1b domain on insulin-
(panel A) or progesterone- (panel B) induced maturation. Each
group of 10^12 oocytes was microinjected with 30 ng of PKCN C1b
domain (open circles) or vehicle (closed circles). Insulin (7.5 WM) or
progesterone (20 WM) were added 30 min later, and GVBD was
monitored for the times indicated in the ¢gure. Results are ex-
pressed as a percentage of oocytes reaching GVBD. Essentially iden-
tical results were obtained in three independent experiments. Experi-
ments using 0.1 WM progesterone gave similar results.
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4. Discussion
Our experiments have clearly shown that the PKCN C1b
domain induces meiotic maturation in X. laevis oocytes.
This is relevant because it suggests that regions within the
regulatory domain of PKCs could trigger biological responses.
Most of the PKC responses have been attributed to phosphor-
ylation events mediated by the C-terminal kinase domain,
whereas the main role of the regulatory domain in PKCs is
to keep the catalytic domain of the enzyme in a ‘close’ inactive
state. Upon binding of phorbol esters or DAG to the C1
domain, PKC becomes active. In this active state, PKC binds
a series of proteins through the regulatory domain which are
probably critical for determining the intracellular localization
of the activated enzyme [4,17,18].
Despite the critical role of the kinase domain in catalysis,
several reports have shown that PKC-mediated responses
could be attributed to the PKC regulatory domain. For ex-
ample, expression of the regulatory domain of PKCN induces
remarkable changes in cell growth and a¡ects malignant
transformation in mammary cancer cells [25,26]. The regula-
tory domains of PKCK and PKCO can regulate phospholipase
D activity [28,44]. It was also reported that overexpression of
the C1 domains of PKCO is su⁄cient to inhibit Golgi-speci¢c
sulfation reactions [45]. In another interesting study, Zeidman
et al. [27] have shown that the C1 domains of PKCO induce
neurite-like processes in neuroblastoma cells, an e¡ect that is
independent of the catalytic domain. Furthermore, the C1a
and C1b domains in PKCO seem to have distinct roles in
this process, suggesting unique interaction properties and
functional roles for each C1 domain. Several reports have
found that C1 domains of PKCs bind speci¢cally to proteins
[20,22,23]. Functional roles have also been demonstrated for
C1 domains of phorbol ester unresponsive proteins. For ex-
ample, the C1 domain of Raf plays an essential role in the
interaction with Ras and in the regulation of the Ras cascade
[46]. Likewise, the C1 domain of phorbol ester unresponsive
atypical PKCs interacts with proteins that regulate their acti-
vation [19]. Taken together, these results revealed a very com-
plex functional role for the C1 domains besides their well-
known role in lipid interactions and phorbol ester/DAG bind-
ing.
We found that microinjection of the PKCN C1b domain
into oocytes potentiates insulin and Ras-mediated maturation,
but not progesterone-induced maturation. In contrast, Pa-
welczyk et al. have reported that an isolated C1b domain of
PKCQ inhibits oocyte maturation after insulin (but not pro-
gesterone) stimulation [21]. It is interesting that despite the
high degree of homology between the C1b domains of
PKCQ and PKCN, both exert opposite responses in the same
model. This is not surprising, however, considering the di¡er-
ential properties of individual C1 domains as phorbol ester
receptors and in protein^protein interaction. Indeed, C1 do-
mains could be phorbol ester/DAG unresponsive (e.g. those in
atypical PKCs, c-Raf or Vav) or even bind phorbol ester
analogs with unique patterns of recognition [2,4,13,14,16].
Striking di¡erences in ligand binding properties have also
been reported for C1a and C1b domains of PKC isozymes,
including the C1 domains of PKCQ [16,47^49]. The di¡erential
roles of C1 domains have also been highlighted in cell models,
as reported in experiments showing that disruption of either
C1a or C1b domain of a single PKC isozyme distinctly a¡ects
translocation, thereby suggesting that each C1 domain has
unique membrane interaction properties [15,16]. In some
cases, such as in PKCO or the novel phorbol ester receptor
L2-chimaerin, C1 domains are critical for determining subcel-
lular compartmentalization after phorbol ester/DAG activa-
tion [45,50]. These conclusions are also supported by our ex-
periments showing that a mutant PKCN C1b domain with
reduced a⁄nity for phorbol esters (W252G-PKCN) is less ef-
fective at inducing oocyte maturation. The low phorbol ester
a⁄nity of this mutant is due to a reduced ability to associate
to membranes (M.G. Kazanietz and P.M. Blumberg, unpub-
lished data), as also reported for mutants in hydrophobic
amino acids in the PKCK C1 domain [51]. Therefore, we
can speculate that association to membranes is probably re-
quired for the C1 domain to exert its e¡ect in oocytes.
It is interesting that the PKCN C1b domain acts selectively
on the insulin pathway but not on the progesterone pathway
in Xenopus oocytes, as also reported with the PKCQ C1b do-
main. Moreover, the PKCN C1b domain markedly synergizes
with Ras to promote meiotic maturation. These experiments
not only rule out the possibility of a non-speci¢c e¡ect of the
PKCN C1b domain after microinjection, but also establish its
speci¢city for the insulin-Ras pathway. Remarkably, the SH2
domain of p85 (PI3K) does not inhibit the e¡ect of the PKCN
Fig. 5. E¡ect of Ras and the SH2 domain of p85 (PI3K) on oocyte
maturation induced by the PKCN C1b domain. Panel A: Oocytes
(in groups of 10^12) were microinjected with 30 ng of PKCN C1b
domain (open circles), 30 ng Ras (Gly-12) (closed circles) or 30 ng
PKCN C1b together with 30 ng Ras (Gly-12) (closed squares), and
GVBD was monitored for the times indicated in the ¢gure. Results
are expressed as a percentage of oocytes reaching GVBD. Two ad-
ditional experiments gave essentially the same results. Panel B: Oo-
cytes in groups of 10 were microinjected with the SH2 domain of
p85 (PI3K) (+) or vehicle (3). After 30 min, insulin (7.5 WM) was
added or 30 ng of PKCN C1b was injected, and GVBD was moni-
tored as previously described. Results were expressed as percentage
of the maximum e¡ect observed with insulin or with the PKCN C1b
domain. A second experiment gave similar results.
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C1b domain, despite its strong inhibition of the insulin re-
sponse. The SH2 domain of p85 binds to insulin receptor
substrates [36], which suggests that the e¡ect of the PKCN
C1b domains occurs further downstream. Although the ex-
periments presented in this paper do not fully elucidate the
mechanisms by which the PKCN C1b domain induces oocyte
maturation, one can envision several hypothetical scenarios
that may explain its e¡ect. One possibility is that the C1
domain is involved in a protein^protein interaction that re-
sults in the activation of the Ras cascade, as described for the
Raf^Ras interaction. Importantly, several reports have re-
vealed a functional interaction between Ras and PKC path-
ways for oocyte maturation as well as cooperation of Ras and
PKC for malignant transformation [42,52,53]. Second, it may
also be possible that expression of the PKCN C1b domain
disrupts an intramolecular association in PKC leading to its
activation, including the potential for disrupting PKC homo-
dimer formation [54]. A third possibility is that the PKCN C1b
domain a¡ects PKC signaling by regulating DAG levels in
membranes. Although further studies will be ultimately neces-
sary to determine the precise mechanism of action of the
PKCN C1b domain in oocyte maturation, this study under-
scores a potential role for motifs in the PKC regulatory do-
mains as regulators of signaling events, and highlights the
concept that C1 regions can be e¡ector domains that confer
selectivity in PKC action.
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